Infinity Pharmaceuticals Inc. (INFIQ)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Adelene Q. Perkins
Employees:
30
784 MEMORIAL DRIVE, CAMBRIDGE, MA 02139
6174531000

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K.

Data derived from most recent annual or quarterly report
Market Cap 4.084 Million Shares Outstanding90.761 Million Avg 30-day Volume 2.875 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.13
Price to Revenue7.3651 Debt to Equity0.0 EBITDA-40.34 Million
Price to Book Value0.0 Operating Margin-1636.668 Enterprise Value1.175 Million
Current Ratio1.65 EPS Growth0.115 Quick Ratio1.471
1 Yr BETA 1.0881 52-week High/Low 1.47 / 0.03 Profit Margin-1593.9276
Operating Cash Flow Growth6.7754 Free Cash Flow to Firm (FCFF) TTM 25.878 Million Free Cash Flow to Equity (FCFE) TTM
Altman Z-Score-63.4032
View SEC Filings from INFIQ instead.

View recent insider trading info

Infinity Pharmaceuticals Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding INFIQ (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding INFIQ

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-09-12 by PERKINS ADELENE Q
  • 4: filed on 2022-08-04 by PELUSO STEPHANE
  • 4: filed on 2022-06-16 by BEIER DAVID W
  • 4: filed on 2022-06-16 by GAYNOR RICHARD
  • 4: filed on 2022-06-16 by AGRESTA SAMUEL
  • 4: filed on 2022-06-16 by SELBY NORMAN C
  • 4: filed on 2022-06-16 by SCHWARTZ BRIAN
  • 4: filed on 2022-03-31 by KANGO SUJAY
  • 3: filed on 2022-03-31 by KANGO SUJAY
  • 4: filed on 2022-01-12 by PERKINS ADELENE Q

    • Events (8k)

  • 8-K: filed on 2023-09-29:
    Item 1.03: Bankruptcy or Receivership
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-09-13:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2023-09-11:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2023-09-01:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
  • 8-K: filed on 2023-07-25:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-24:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-14:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-07-03:
    Item 8.01: Other Events
  • 8-K: filed on 2023-06-30:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2023-06-20:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    PERKINS ADELENE Q

    • Director
    		 1,191,738 2023-09-08 1

    PELUSO STEPHANE CHIEF SCIENTIFIC OFFICER

    • Officer
    		 89,098 2022-08-02 0

    BEIER DAVID W

    • Director
    		 53,775 2022-06-16 0

    SELBY NORMAN C

    • Director
    		 70,000 2022-06-16 0

    EVNIN ANTHONY B

    • Director
    		 260,403 2022-06-16 0

    SCHWARTZ BRIAN

    • Director
    		 75,919 2022-06-16 0

    GAYNOR RICHARD

    • Director
    		 45,000 2022-06-16 0

    AGRESTA SAMUEL

    • Director
    		 55,593 2022-06-16 0

    KANGO SUJAY

    • Director
    		 144,787 2022-03-30 0

    BLOCH LAWRENCE E PRESIDENT

    • Officer
    		 1,093,308 2022-01-11 0

    TASKER SETH A CHIEF BUSINESS OFFICER

    • Officer
    		 338,275 2022-01-11 0

    ILARIA ROBERT JR. CHIEF MEDICAL OFFICER

    • Officer
    		 87,472 2022-01-11 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BVF I GP LLC

    BIOTECHNOLOGY VALUE FUND II LP

    BVF II GP LLC

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF GP HOLDINGS LLC

    BVF INC/IL

    LAMPERT MARK N

    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    		 No longer subject to file 2021-02-17 0

    VENUTI MICHAEL C

    • Director
    		 0 2020-06-17 0

    KUTOK JEFFERY CHIEF SCIENTIFIC OFFICER

    • Officer
    		 88,120 2020-01-10 0

    KAUFFMAN MICHAEL

    • Director
    		 0 2019-06-13 0

    BERKOWITZ JEFFREY

    • Director
    		 85,238 2019-06-13 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    		16,371,704 2018-12-13 0

    SMITH IAN F

    • Director
    		 45,845 2018-06-12 0

    BASELGA JOSE

    • Director
    		 0 2017-01-06 0

    ADAMS JULIAN PRESIDENT OF R&D

    • Officer
    		 No longer subject to file 2016-10-31 0

    LANDER ERIC S

    • Director
    		 No longer subject to file 2016-06-17 0

    LINDBLOM CHRISTOPHER M PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 0 2016-05-02 0

    BERTRAND WILLIAM C JR GENERAL COUNSEL

    • Officer
    		 No longer subject to file 2015-10-19 0

    PALOMBELLA VITO J. CHIEF SCIENTIFIC OFFICER

    • Officer
    		 No longer subject to file 2015-06-15 0

    FYFE GWEN A.

    • Director
    		 No longer subject to file 2015-06-15 0

    LAM WINSTON K.C. GENERAL COUNSEL

    • Officer
    		 0 2015-04-15 0

    ROTH DAVID CHIEF MEDICAL OFFICER

    • Officer
    		 No longer subject to file 2015-01-14 0

    SANTABARBARA PEDRO CHIEF MEDICAL OFFICER

    • Officer
    		 No longer subject to file 2014-01-10 0

    BABLER MARTIN

    • Director
    		 0 2013-06-11 0

    LYNCH THOMAS J. JR.

    • Director
    		 0 2013-06-11 0

    BEACON CO

    • 10% Owner
    		 No longer subject to file 2013-04-16 0

    ROSEBAY MEDICAL CO L.P.

    • 10% Owner
    		 No longer subject to file 2013-04-16 0

    HAMERMESH JOSHUA VP, BUSINESS & CORPORATE DEV

    • Officer
    		 0 2013-01-04 0

    TUCKER WINSELOW S. JR. VICE PRESIDENT, MARKETING

    • Officer
    		 0 2013-01-04 0

    HOLTZMAN STEVEN H

    • Director
    		 3,945 2012-05-31 0

    LEE PATRICK PAK-TIN

    • Director
    		 0 2012-05-16 0

    QUIRK GERALD E SEE REMARKS

    • Officer
    		 0 2012-01-06 0

    LEVINE ARNOLD J

    • Director
    		 0 2011-05-18 0

    TANANBAUM JAMES B

    • Director
    		 0 2011-05-18 0

    MOSS FRANKLIN

    • Director
    		 0 2010-05-25 0

    TONG JEFFREY K VP, COR. & PRODUCT DEVELOPMENT

    • Officer
    		 0 2010-01-05 0

    HIXSON HARRY F JR

    • Director
    		 0 2009-06-17 0

    SATO VICKI L

    • Director
    		 0 2008-05-22 0

    ROSENMAN HERM

    • Director
    		 3,750 2007-09-12 0

    DANIEL D RONALD

    • Director
    		 1,875 2007-06-04 0

    PROSPECT VENTURE PARTNERS II LP

    PROSPECT VENTURE PARTNERS LP

    PROSPECT MANAGEMENT CO II LLC

    PROSPECT MANAGEMENT CO LLC

    • 10% Owner
    		 2,102,398 2006-09-12 0

    BARKAS ALEXANDER E

    • 10% Owner
    		 2,129,336 2006-09-12 0

    SCHNELL DAVID

    • 10% Owner
    		 2,129,336 2006-09-12 0

    BURKE THOMAS JOSEPH ASSISTANT TREASURER

    • Officer
    		 0 2006-09-12 0

    NEALE RICHARD VICE PRESIDENT

    • Officer
    		 39,635 2006-08-14 0

    DOLLERY COLIN

    • Director
    		 10,000 2006-05-11 0

    LEWIS ALAN

    • Director
    		 10,000 2006-05-11 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 22:15:04 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 21:45:04 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 21:15:03 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 20:45:04 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 20:15:05 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 19:45:04 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 19:15:04 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 18:45:05 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 18:15:03 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 17:45:04 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 17:15:03 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 16:45:04 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 16:15:03 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 15:45:04 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 15:15:03 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 14:45:03 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 14:15:04 UTC 1.0539 4.2661 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 13:45:04 UTC 1.0465 4.2735 1700000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 13:15:04 UTC 1.0465 4.2735 1500000
    INFINITY PHARMACEUTICALS INC INFIQ 2023-11-27 12:45:04 UTC 1.0465 4.2735 25000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments